Short answer
Solventum (SOLV) filed its fiscal 2025 10-K annual report with the SEC on Feb 27, 2026. It reported revenue of $8.3B (+0.9% year over year) and net income of $1.6B.
- Top risk flagged: 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
FY2025 key financial metrics · XBRL
- Revenue
- $8.3B
- +0.9% YoY
- Net income
- $1.6B
- +224.8% YoY
- Operating margin
- 26.2%
- +13.6 pp YoY
- Gross margin
- 53.5%
- −2.2 pp YoY
- EPS (diluted)
- $8.88
- +221.7% YoY
- ROE
- 30.8%
- +14.6 pp YoY
- Operating cash flow
- $369M
- −68.9% YoY
Source: XBRL data from the Solventum (SOLV) FY2025 10-K on SEC EDGAR. USD.
Solventum FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Global healthcare company (~20,000 employees, ~$0 revenue figures disclosed) across three segments: MedSurg 57.9%, Health Information Systems 16.3%, Dental Solutions 16.2% of 2025 sales
- Two major portfolio moves in 2025: acquired Acera Surgical (bioscience, adds synthetic tissue matrices) and divested Purification & Filtration business to Thermo Fisher Scientific
- Still separating from 3M parent: actively transitioning off 3M infrastructure under Transition and Distribution Agreement and Transition Contract Manufacturing Agreement, a key ongoing operational risk
- R&D team of ~2,000 employees; sales presence in 90+ countries with ~40% of workforce having 10+ years tenure, signaling stable legacy talent base during post-spin transition
- U.S. Supreme Court ruled Feb 20, 2026 that IEEPA does not authorize presidential tariffs: Solventum explicitly flagged potential tariff recovery but stated financial impact "cannot be reasonably estimated," a rare forward-looking legal disclosure embedded in the business section
Management Discussion & Analysis
- Revenue $8,325M, up 0.9% YoY ($71M increase); organic growth 3.3%, offset by -3.0% divestiture impact from Purification & Filtration sale
- Operating margin 26.2% vs 12.6% in 2024 (includes $1.5B gain on P&F sale); SG&A 37.0% vs 33.7%; R&D 8.9% vs 9.4%
- Best segment: Health Information Systems, operating margin 36.5% vs 33.0%, sales +4.1% to $1,360M; worst: MedSurg margin 16.8% vs 19.1%, despite 3.9% sales growth to $4,817M
- Investing activities $2,797M inflow (vs -$380M in 2024) driven by ~$4B P&F sale proceeds; financing outflows -$3,057M including $2.0B senior note repayment and $1,070M term loan repayments; cash position $878M at year-end
- Key risks: tariff impact ~$55M on product costs, ongoing 3M supply agreement mark-ups, debt servicing burden, and brand transition from 3M; no explicit forward guidance provided
Risk Factors
- 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
- $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility
- U.S.-China trade tensions and tariffs actively impacting Solventum and suppliers; further escalation cited as material risk to global operations
- AI-enabled new entrants threatening Health Information Systems segment specifically; failure to match competitor AI integration risks customer loss
- PFAS indemnification from 3M expires after 2025 product sales; ongoing PFAS use in components (wound therapy, temp management devices) creates unindemnified regulatory and litigation exposure
Generated from the filing text; verify against the original. How to read a 10-K
Other Solventum annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.